This week, we will be discussing a randomized controlled trial of eculizumab in STEC-HUS. Will eculizumab manage to surpass its well-established reputation as expensivumab and demonstrate some positive results?
Background
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
Background
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
Background
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
